Clinical Efficacy & Neurobiological Correlates of sequential treatment with cathodal tDCS primed iTBS and ECT in Treatment-Resistant Depression

Department of Psychiatry National Institute of Mental Health and Neuro Sciences0 个研究点目标入组 0 人开始时间: 待定最近更新: 2022年10月17日

试验速览

暂无简介。

•1.Major Depressive Disorder Diagnosis (DSM-5)
•2.Right-handed (Edinburgh Handedness Inventory)
•3.Hamilton Depression Rating Scale (HAMD-17) score of 18 or more
•4.No clinical response to an adequate dose of two antidepressant medications (based on antidepressant treatment history form score) OR Unable to tolerate at least two separate trials of antidepressants of inadequate dose and duration, and if they are currently on a stable antidepressant regimen for at least 4 weeks before which will be continued during treatment
•5.Capacity to consent for research studies as per the assessment using the University of California, San Diego Brief Assessment of Capacity to Consent (UBACC)
•6. Written informed consent.

•1.Resistant to 3 or more antidepressants or to an adequate ECT trial
•2.Suicidal intent (HAMD suicide item score of 3 or 4) / any psychiatric emergency
•3.Bipolar depression;
•4.Psychotic disorder or symptoms;
•5.Neurological/clinical evidence of other medical comorbidity that could substantially influence depression;
•6.Unstable medical illness;
•7.Co-prescribed BZD >1-mg clonazepam equivalents or anti-epileptic drugs;
•8.Severe general medical/neurological comorbidity that precludes ECT or has an effect on cognition and behavior;
•9.Current psychoactive substance dependence (except caffeine or nicotine);
•10.Pregnancy or Post-partum Period;
•11.Co-morbid neurological/medical disease that can affect the brain structure/function;
•12.Any contraindication for Magnetic Resonance Imaging;
•13.Any contraindication for Transcranial Magnetic Stimulation;
•14.Any contraindication for Transcranial Direct Current Stimulation

发起方

Department of Psychiatry National Institute of Mental Health and Neuro Sciences